A University of Arkansas for Medical Sciences (UAMS) researcher has been awarded more than $3 million in grants for myeloma research.
Myeloma Center researcher director Fenghuang “Frank” Zhan, M.D received approximately $3.14 million in grants from two government agencies. The funding will be used to study the molecular genetics and drug resistance of multiple myeloma, a form of blood-related cancer.
“Once the biology of myeloma stem cells is better understood, more novel therapeutic targets can be created and tested, with the ultimate goal being to develop a novel therapy and prevent myeloma relapses,” Zhan said in a statement.
Part of the funding comes from the U.S. Department of Defense and part comes from the National Institutes of Health. The DOD provided $1.4 million, while the NIH has provided $1.74 million.
The DOD grant will run through 2023, and this research will focus on the biology of myeloma cancer cells that are capable of surviving chemotherapy with an aim of developing a cure to eliminate these cells.
The NIH grant will run through 2025. For this research, Zhan will focus on two specific genes and what role they play in driving myeloma.